Mirae Asset Global Investments Co. Ltd. Has $227,000 Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Mirae Asset Global Investments Co. Ltd. reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,223 shares of the biotechnology company’s stock after selling 3,347 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Sarepta Therapeutics were worth $227,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SRPT. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after acquiring an additional 117,904 shares in the last quarter. Capital International Investors grew its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock worth $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after acquiring an additional 285,100 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Sarepta Therapeutics by 0.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,956,583 shares of the biotechnology company’s stock valued at $237,901,000 after acquiring an additional 10,343 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,706,353 shares of the biotechnology company’s stock valued at $207,538,000 after buying an additional 9,999 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $18.22 on Monday. The stock has a market cap of $1.79 billion, a PE ratio of -6.77 and a beta of 0.45. The company’s fifty day moving average is $35.34 and its 200 day moving average is $74.80. Sarepta Therapeutics, Inc. has a 52 week low of $16.88 and a 52 week high of $154.90. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The business had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS. Research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Analyst Upgrades and Downgrades

SRPT has been the topic of a number of recent research reports. Oppenheimer dropped their price target on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an “outperform” rating on the stock in a research note on Friday, June 20th. Piper Sandler lowered shares of Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $70.00 to $36.00 in a report on Monday, June 16th. The Goldman Sachs Group lowered shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating and set a $29.00 target price on the stock. in a report on Tuesday, June 17th. Royal Bank Of Canada decreased their target price on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 7th. Finally, UBS Group decreased their target price on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Hold” and a consensus target price of $60.88.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.